IOVA Stock Balance Sheets

Iovance Biotherapeutics Quarterly Balance Sheets Chart

Quarterly

Annual

Cash and Cash Eq

Account Payables

Inventory

Iovance Biotherapeutics Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31

assets

current assets
cash and cash equivalents	132,469,000	171,668,000	115,694,000	164,186,000	228,678,000	134,188,000	114,888,000	267,720,000	230,010,000	543,484,000	231,731,000	118,366,000	108,075,000	92,360,000	78,229,000	58,590,000	82,763,000	131,954,000	67,329,000	68,310,000	160,614,000	52,540,000	13,969,000	38,889,000	76,912,000	54,093,000	82,152,000	80,738,000	246,017,000	297,082,000	145,373,000	163,380,000	114,285,000	107,099,000	106,717,000	92,895,000	101,222,000	13,642,000	10,210,000	12,556,290	111,280,443	44,909,147	18,440,361	17,943,877	19,672,177	129,804	15,739		910,608	268,565	722,994	1,292,469	795,943	209,263	311,799
trade accounts receivable	59,938,000	70,938,000	69,340,000	55,768,000	31,604,000	234,000	151,000		33,000
short-term investments	168,714,000	188,045,000	208,087,000	233,302,000	183,864,000	222,007,000	164,979,000	93,654,000	20,884,000	82,808,000	240,114,000	241,807,000	316,383,000	389,829,000	426,181,000	517,859,000	573,605,000	461,976,000	562,108,000	645,838,000	611,265,000	193,112,000	293,112,000	322,985,000	327,241,000	385,925,000	386,371,000	179,262,000	30,082,000				14,732,000	40,098,000	59,753,000	86,387,000
inventory	49,833,000	65,545,000	51,520,000	38,578,000	27,854,000	17,617,000	10,372,000	9,195,000	9,720,000
prepaid expenses and other assets	11,546,000	15,894,000	12,377,000	6,744,000	10,183,000	11,487,000	17,458,000	12,017,000	14,231,000	11,489,000	7,271,000	9,711,000	7,135,000	7,779,000	3,546,000	6,577,000	10,272,000	11,288,000	6,663,000	9,442,000	10,775,000	10,729,000	9,412,000				6,851,000	5,863,000	3,682,000	5,644,000
total current assets	422,500,000	512,649,000	457,018,000	498,578,000	482,257,000	385,533,000	307,848,000	382,586,000	274,878,000	637,781,000	479,116,000	369,884,000	431,593,000	489,968,000	507,956,000	583,026,000	666,640,000	605,218,000	636,100,000	723,590,000	782,654,000	256,381,000	316,493,000	367,307,000	410,938,000	444,753,000	475,374,000	265,863,000	279,781,000	302,726,000	149,290,000	171,375,000	135,434,000	152,593,000	169,512,000	180,556,000	192,350,000	103,977,000	110,391,000	112,714,536	111,409,326	44,975,281	18,519,571	18,067,968	19,845,893	138,682	24,367	34,050	3,298,108	326,065	788,286	1,300,916	801,093	214,413	316,949
property and equipment	122,473,000	111,584,000	109,081,000	112,520,000	110,960,000	111,789,000	114,030,000	113,142,000	112,549,000	109,923,000	105,232,000	100,746,000	101,154,000	102,757,000	100,938,000	88,034,000	80,120,000	72,750,000	59,159,000	39,112,000	18,726,000	13,607,000	8,536,000	5,856,000	4,472,000	3,504,000	2,683,000	2,640,000	2,706,000	2,247,000	2,450,000	2,595,000	2,578,000	2,796,000	2,374,000	1,769,000
intangible assets	296,253,000	285,356,000	282,398,000	306,639,000	295,299,000	294,303,000	229,258,000	223,610,000	235,511,000
operating lease right-of-use assets	49,949,000	50,903,000	55,201,000	66,743,000	69,123,000	71,516,000	62,515,000	66,265,000	67,631,000	70,431,000	73,015,000	68,268,000	70,845,000	73,475,000	68,983,000	72,423,000	52,508,000	55,131,000	54,756,000	10,682,000	7,480,000	9,305,000	10,695,000	13,738,000	11,719,000	9,957,000
restricted cash	5,944,000	559,000	6,359,000	6,355,000	74,000	6,430,000	66,430,000	66,430,000	66,430,000	6,430,000	6,430,000	6,430,000	6,430,000	6,084,000	6,084,000	6,084,000	6,084,000	6,084,000	5,525,000	5,525,000	5,525,000	5,525,000	5,450,000	5,450,000	5,450,000																								2,320,000
long-term assets	10,318,000	426,000	369,000	280,000	327,000	259,000	270,000	282,000	294,000	202,000	189,000	596,000	856,000	1,266,000	1,784,000	1,011,000	1,150,000	1,163,000	12,918,000	3,385,000	3,182,000	3,480,000	3,481,000	3,395,000	3,345,000	3,288,000	2,764,000	2,331,000	2,264,000	2,275,000	3,633,000
total assets	907,437,000	966,740,000	910,426,000	991,115,000	964,322,000	869,830,000	780,351,000	852,315,000	757,293,000	824,767,000	663,982,000	545,924,000	610,878,000	701,251,000	777,333,000	828,825,000	852,790,000	750,573,000	768,458,000	782,294,000	817,567,000	288,298,000	344,655,000	395,746,000	435,924,000	461,502,000	480,821,000	270,834,000	284,751,000	307,248,000	155,373,000	173,970,000	138,012,000	155,389,000	171,886,000	182,325,000	193,542,000	105,653,000	112,224,000	114,739,592	113,537,586	46,506,847	18,535,342	18,082,596	19,873,649	168,626	65,611	76,847	3,438,596	466,166	930,205	1,460,952	1,020,235	433,729	536,438
liabilities and stockholders’ equity
current liabilities
accounts payable	32,004,000	28,489,000	27,509,000	31,686,000	20,416,000	25,700,000	33,123,000	19,274,000	31,157,000	31,572,000	26,603,000	24,255,000	20,009,000	20,454,000	27,377,000	12,181,000	21,914,000	13,369,000	13,513,000	24,794,000	10,238,000	10,614,000	15,567,000	9,921,000	12,782,000	7,589,000	2,739,000	6,014,000	5,196,000	6,576,000	1,232,000	2,905,000	3,695,000	2,174,000	863,000	228,000	725,000	958,000	1,161,000	1,156,922	1,107,370	1,248,413	440,550	286,325	412,976	1,550,865	609,266	504,252	206,864	130,638	72,493	30,292	25,492	15,777	17,061
accrued expenses and other liabilities	89,081,000	84,705,000	81,936,000
note payable - current	1,000,000	1,000,000
operating lease liabilities	7,070,000	8,499,000	12,896,000	11,551,000	11,436,000	11,078,000	7,777,000	10,468,000	10,866,000	12,614,000	12,587,000	7,171,000	6,483,000	7,710,000	5,057,000								7,252,000	8,370,000	7,484,000	6,059,000
total current liabilities	129,155,000	122,693,000	122,341,000	118,056,000	93,639,000	83,214,000	110,306,000	90,955,000	88,643,000	87,274,000	91,485,000	79,245,000	64,192,000	77,075,000	89,200,000	64,766,000	60,534,000	55,059,000	54,871,000	64,390,000	54,905,000	39,545,000	39,084,000	34,613,000	33,836,000	22,137,000	14,398,000	16,674,000	14,182,000	14,690,000	9,892,000	8,529,000	8,860,000	5,503,000	4,968,000	3,194,000	4,606,000	1,630,000	2,855,000	1,866,196	1,910,717	1,661,760	1,156,472	1,109,486	2,269,932	3,509,085	16,683,973	17,335,298	9,129,321	1,870,111	771,114	822,867	572,222	15,777	35,198
non-current liabilities
operating lease liabilities – non-current	45,096,000	44,220,000	44,365,000	66,389,000	69,246,000	72,291,000	67,085,000	68,009,000	68,844,000	69,612,000	71,859,000	71,943,000
deferred tax liabilities	34,698,000	31,962,000	32,315,000	32,215,000	31,897,000	33,301,000	17,347,000	18,343,000	20,237,000
long-term note payable			1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000
total non-current liabilities	79,794,000	76,182,000	77,680,000	99,604,000	102,143,000	106,592,000	85,432,000	87,352,000	90,081,000	70,612,000	72,859,000	72,943,000	73,996,000	72,184,000	66,474,000	65,729,000	47,843,000	48,083,000	57,089,000	6,063,000	4,353,000	5,440,000	6,600,000	6,070,000	4,666,000	4,433,000	230,000
total liabilities	208,949,000	198,875,000	200,021,000	217,660,000	195,782,000	189,806,000	195,738,000	178,307,000	178,724,000	157,886,000	164,344,000	152,188,000	138,188,000	149,259,000	155,674,000	130,495,000	108,377,000	103,142,000	111,960,000	70,453,000	59,258,000	44,985,000	45,684,000	40,683,000	38,502,000	26,570,000	14,628,000
commitments and contingencies
stockholders’ equity
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of june 30, 2025 and december 31, 2024
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 1,932,667 and 2,842,158 shares issued and outstanding as of june 30, 2025 and december 31, 2024 respectively	2,000
common stock	14,000	14,000	13,000	13,000	12,000	12,000	11,000	11,000	9,000	9,000	8,000	7,000	7,000	7,000	7,000	7,000	7,000	6,000	6,000	6,000	6,000	5,000	5,000	5,000	5,000	5,000	5,000	4,000	4,000	3,000	3,000	3,000	3,000	3,000	3,000	3,000	3,000	2,000	2,000	1,964	1,870								3,291	3,236	2,945	3,068
accumulated other comprehensive loss	20,859,000	6,294,000	-1,046,000	16,242,000	526,000	116,000				-126,000	-902,000	-2,038,000	-2,697,000	-2,343,000									220,000				-42,000	-120,000	-3,000
additional paid-in capital	3,289,986,000	3,262,270,000	3,095,987,000	3,063,190,000	2,990,451,000	2,805,244,000	2,594,448,000	2,579,087,000	2,360,468,000	2,342,703,000	2,068,867,000	1,858,783,000	1,838,778,000	1,818,377,000	1,794,695,000	1,771,440,000	1,731,363,000	1,552,968,000	1,486,662,000	1,473,472,000	1,461,207,000	882,599,000	869,354,000	861,859,000	854,596,000	844,789,000	838,984,000	594,455,000	576,917,000	568,243,000	394,651,000	388,756,000	330,318,000	327,673,000	323,994,000	320,140,000	311,268,000	207,950,000	204,929,000	200,832,015	193,239,795	121,160,415	86,029,444	83,346,665	81,884,897	40,582,801	16,357,027	15,887,542	13,330,974	11,799,331	2,402,918	2,317,493	1,385,534	641,755	640,414
accumulated deficit	-2,612,373,000	-2,500,715,000	-2,384,552,000	-2,305,993,000	-2,222,452,000	-2,125,351,000	-2,012,375,000	-1,895,996,000	-1,782,236,000	-1,675,708,000	-1,568,338,000	-1,463,019,000	-1,363,401,000	-1,264,052,000	-1,172,445,000	-1,073,115,000	-986,993,000	-905,642,000	-830,193,000	-761,796,000	-703,225,000	-640,207,000	-570,612,000	-507,044,000	-457,557,000	-410,006,000	-372,760,000	-340,185,000	-306,355,000	-275,695,000	-249,180,000	-223,326,000	-201,177,000	-177,800,000	-157,116,000	-141,428,000	-122,669,000	-104,222,000	-95,845,000	-88,227,444	-81,859,953	-76,561,894	-68,896,868	-66,786,699	-64,527,185	-44,569,042	-33,476,539	-33,149,255	-19,024,990	-13,206,512	-2,246,772	-1,682,476	-940,554	-226,797	-142,168
total stockholders’ equity	698,488,000	767,865,000	710,405,000	773,455,000	768,540,000	680,024,000	584,613,000	674,008,000	578,569,000	666,881,000	499,638,000	393,736,000	472,690,000	551,992,000	621,659,000	698,330,000	744,413,000	647,431,000	656,498,000	711,841,000	758,309,000	243,313,000	298,971,000	355,063,000	397,422,000	434,932,000	466,193,000	254,160,000	270,569,000	292,558,000	145,481,000	165,441,000	129,152,000	149,886,000	166,918,000	179,131,000	188,936,000		109,369,000	112,873,396										-1,403,945	159,091	638,085
total liabilities and stockholders’ equity	907,437,000	966,740,000	910,426,000	991,115,000	964,322,000	869,830,000	780,351,000	852,315,000	757,293,000	824,767,000	663,982,000	545,924,000	610,878,000	701,251,000	777,333,000	828,825,000	852,790,000	750,573,000	768,458,000	782,294,000	817,567,000	288,298,000	344,655,000	395,746,000	435,924,000	461,502,000	480,821,000	270,834,000	284,751,000	307,248,000	155,373,000	173,970,000	138,012,000	155,389,000	171,886,000	182,325,000	193,542,000		112,224,000	114,739,592										466,166	930,205	1,460,952
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of march 31, 2025 and december 31, 2024
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 1,932,667 and 2,842,158 shares issued and outstanding as of march 31, 2025 and december 31, 2024 respectively		2,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of december 31, 2024 and december 31, 2023
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of december 31, 2024 and december 31, 2023			3,000
accrued expenses				74,819,000	61,787,000	46,436,000	69,406,000	61,213,000	46,620,000	43,088,000	52,295,000	47,819,000	37,700,000	48,911,000	56,766,000	45,969,000	34,192,000	35,774,000	35,074,000	32,400,000	38,794,000	22,500,000	16,265,000	16,322,000	13,570,000	8,489,000	11,659,000	10,660,000	8,986,000	8,114,000	8,660,000	5,624,000	5,165,000	3,329,000	4,105,000	2,966,000	3,881,000	586,000	1,608,000	623,774	717,847	327,847	715,922	823,161	1,856,956	1,958,220	502,347	279,480
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of september 30, 2024 and december 31, 2023
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of september 30, 2024 and december 31, 2023				3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of june 30, 2024 and december 31, 2023
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of june 30, 2024 and december 31, 2023					3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of march 31, 2024 and december 31, 2023
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of march 31, 2024 and december 31, 2023						3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of december 31, 2023 and december 31, 2022
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of december 31, 2023 and december 31, 2022							3,000
accumulated other comprehensive income							2,526,000	-9,097,000	325,000						-601,000	-5,000	33,000	96,000	19,000	155,000	317,000	912,000		239,000	372,000	138,000								2,000	29,000	163,000	78,000	48,000	38,000	21,704
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of september 30, 2023 and december 31, 2022
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of september 30, 2023 and december 31, 2022								3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of june 30, 2023 and december 31, 2022
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of june 30, 2023 and december 31, 2022									3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of march 31, 2023 and december 31, 2022
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of march 31, 2023 and december 31, 2022										3,000
long-term investments														27,701,000	91,588,000	78,247,000	46,288,000	10,227,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of december 31, 2022 and december 31, 2021
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of december 31, 2022 and december 31, 2021											3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of september 30, 2022 and december 31, 2021
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of september 30, 2022 and december 31, 2021												3,000
operating lease liabilities – noncurrent													72,996,000	71,184,000	65,474,000	64,729,000	46,843,000	47,083,000	45,375,000	3,711,000	2,001,000	3,088,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of june 30, 2022 and december 31, 2021
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of june 30, 2022 and december 31, 2021													3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of march 31, 2022 and december 31, 2021
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 shares issued and outstanding as of march 31, 2022 and december 31, 2021														3,000
other liabilities																			11,714,000	2,352,000	2,352,000	2,352,000	2,352,000	53,000	53,000	53,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of december 31, 2021 and december 31, 2020
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 and 3,581,119 shares issued and outstanding as of december 31, 2021 and december 31, 2020															3,000
operating lease liabilities - current																6,616,000	4,428,000	5,916,000	6,284,000	7,196,000	5,873,000	6,431,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of september 30, 2021 and december 31, 2020
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 and 3,581,119 shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively																3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of june 30, 2021 and december 31, 2020
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 and 3,581,119 shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively																	3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of march 31, 2021 and december 31, 2020
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 2,842,158 and 3,581,119 shares issued and outstanding as of march 31, 2021 and december 31, 2020, respectively																		3,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of december 31, 2020 and december 31, 2019
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 3,581,119 shares issued and outstanding as of december 31, 2020 and december 31, 2019																			4,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of september 30, 2020 and december 31, 2019
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 3,581,119 shares issued and outstanding as of september 30, 2020 and december 31, 2019																				4,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of june 30, 2020 and december 31, 2019
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 3,581,119 shares issued and outstanding as of june 30, 2020 and december 31, 2019																					4,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of march 31, 2020 and december 31, 2019
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 3,581,119 shares issued and outstanding as of march 31, 2020 and december 31, 2019																						4,000
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of december 31, 2019 and december 31, 2018
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated, 3,581,119 and 5,854,845 shares issued and outstanding as of december 31, 2019 and december 31, 2018																							4,000
prepaid expenses and other current assets																								5,433,000	6,785,000	4,735,000					3,917,000	7,995,000	6,417,000	5,396,000	3,042,000	1,274,000	782,000	277,000				66,134		114,091
series a convertible preferred stock, 0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of september 30, 2019 and december 31, 2018
series b convertible preferred stock, 0.001 par value; 11,500,000 shares designated; 3,581,119 and 5,854,845 shares issued and outstanding as of september 30, 2019 and december 31, 2018																								4,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 194 shares issued and outstanding as of june 30, 2019 and december 31, 2018
series b convertible preferred stock, 0.001 par value; 50,000,000 shares authorized; 5,854,845 shares issued and outstanding as of june 30, 2019 and december 31, 2018																									6,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 194 shares issued and outstanding as of march 31, 2019; and december 31, 2018
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized; 5,854,845 shares issued and outstanding as of march 31, 2019 and december 31, 2018 (aggregate liquidation value of 27,811);																										6,000
deferred rent																											230,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 194 shares issued and outstanding as of december 31, 2018; 1,694 shares issued and outstanding december 31, 2017
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized; 5,854,845 shares issued and outstanding as of december 31, 2018; 7,378,241 shares issued and outstanding december 31, 2017 (aggregate liquidation value of 27,811);																											6,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 194 shares issued and outstanding as of september 30, 2018; 1,694 shares issued and outstanding december 31, 2017
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized; 5,854,845 shares issued and outstanding as of september 30, 2018; 7,378,241 shares issued and outstanding december 31, 2017 (aggregate liquidation value of 27,811);																												6,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 194 shares issued and outstanding as of june 30, 2018; 1,694 shares issued and outstanding december 31, 2017
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized; 6,127,692 shares issued and outstanding as of june 30, 2018; 7,378,241 shares issued and outstanding december 31, 2017 (aggregate liquidation value of 29,107);																													6,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 1,694 shares issued and outstanding, as of march 31, 2018 and december 31, 2017
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized, 7,378,241 issued and outstanding as of march 31, 2018 and december 31, 2017																														7,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 1,694 shares issued and outstanding, as of december 31, 2017 and december 31, 2016, respectively
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized, 7,378,241 and 7,946,673 shares issued and outstanding as of december 31, 2017 and december 31, 2016, respectively																															7,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 1,694 shares issued and outstanding, as of september 30, 2017 and december 31, 2016, respectively
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized, 7,946,673 shares issued and outstanding as of september 30, 2017 and december 31, 2016, respectively																																8,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 1,694 shares issued and outstanding, as of june 30, 2017 and december 31, 2016, respectively
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized, 7,946,673 shares issued and outstanding as of june 30, 2017 and december 31, 2016, respectively																																	8,000
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 1,694 shares issued and outstanding, as of march 31, 2017 and december 31, 2016, respectively
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized, 7,946,673 shares issued and outstanding as of march 31, 2017 and december 31, 2016, respectively																																		8,000
shares authorized, 62,350,149 and 62,248,074 shares issued and outstanding as of march 31, 2017 and december 31, 2016, respectively
series a convertible preferred stock, 0.001 par value; 17,000 shares authorized, 1,694 shares issued and outstanding, respectively
series b convertible preferred stock, 0.001 par value; 11,500,000 shares authorized, 7,946,673 and 0 shares issued and outstanding as of december 31, 2016 and 2015, respectively																																			8,000
shares authorized, 62,248,074 and 48,547,720 shares issued and outstanding as of december 31, 2016 and 2015, respectively
series a preferred stock, 0.001 par value; 17,000 shares authorized, 1,694 shares issued and outstanding, respectively
series b preferred stock, 0.001 par value; 11,500,000 shares authorized, 7,946,673 and 0 shares issued and outstanding (aggregate liquidation value of 37,747), respectively																																				8,000
common stock to be issued, 303,125 shares																																				245,000	245,000	245,000		245,153	245,153	245,153	245,153	245,153	245,153	245,153
money market funds																																					19,744,000	19,945,000	20,562,000	7,476,855
short-term investments available for sale																																					70,602,000	70,113,000	79,374,000	92,302,982
property and equipment, net of accumulated depreciation and amortization of 1,643 and 1,103, respectively																																					1,192,000
series b preferred stock, 0.001 par value; 11,500,000 shares authorized, 11,368,633 and 0 shares issued and outstanding (aggregate liquidation value of 54,001), respectively																																					11,000
property and equipment, net of accumulated depreciation of 1,103 and 104, respectively																																						1,676,000
liabilities and stockholders' equity
accrued payable to officers and former directors																																						86,000	86,000	85,500	85,500	85,500
stockholders' equity
preferred stock, 0.001 par value; 50,000,000 shares authorized, 1,694 and 5,694 shares issued and outstanding, respectively
total stockholders' equity																																						104,023,000			111,626,869	44,845,087	17,378,870	16,806,053	17,603,717				-5,690,725				448,013	417,952	501,240
total liabilities and stockholders' equity																																						105,653,000			113,537,586	46,506,847	18,535,342	18,082,596	19,873,649				3,438,596				1,020,235	433,729	536,438
prepaid and other current assets																																							245,000
property and equipment, net of accumulated depreciation of 794 and 103, respectively																																							1,833,000
preferred stock, 0.001 par value; 50,000,000 shares authorized, 3,694 shares and 5,694 shares issued and outstanding, respectively																																								4	4
common stock to be issued, 245,153 shares																																							245,000
prepaid expenses and deposits																																								378,409	128,883
property and equipment, net of accumulated depreciation of 529,866 and 104,223, respectively																																								2,025,056
property and equipment, net of accumulated depreciation of 289,672 and 104,223																																									2,128,260
property and equipment, net of accumulated depreciation of 104,223 and 16,002																																										1,531,566
preferred stock, 0.001 par value; 50,000,000 shares authorized,
5,694 shares and 17,000 shares issued and outstanding, respectively																																										6
33,750,188 and 20,023,958 shares issued and outstanding, respectively																																										1,407
deposits																																											9,744	10,000	15,000	5,000
prepaid expenses																																											69,466		158,716	3,878					7,792	3,447	5,000	5,000	5,000
property and equipment, net of accumulated depreciation of 33,730 and 16,002																																											15,771
5,800 shares and 17,000 shares issued and outstanding, respectively																																											6
27,226,350 and 20,023,958 shares issued and outstanding, respectively																																											1,135
the accompanying notes are an integral part of these financial statements.
property and equipment, net of accumulated depreciation of 32,567 and 16,002																																												14,628
accrued compensation payable in shares of stock																																												167,057
13,300 shares and 17,000 shares issued and outstanding, respectively																																												13
22,092,958 and 20,023,958 shares issued and outstanding, respectively																																												921
property and equipment, net of accumulated depreciation of 16,002 and 8,915																																													27,756
7% senior secured convertible promissory notes
12% secured promissory note
september 2012 secured promissory note
accrued interest and penalty
17,000 shares and no shares issued and outstanding, respectively																																													17
20,023,958 and 818,806 shares issued and outstanding, respectively																																													835
property and equipment, net of accumulated depreciation of 13,814 and 8,915																																														29,944
liabilities and stockholders' deficiency
stockholders' deficiency
no shares issued and outstanding
15,072,911 and 818,806 shares issued and outstanding, respectively																																														629
common stock subscribed for, 400,000 shares																																														400,000
total stockholders' deficiency																																														-3,340,459	-16,618,362	-17,258,451
total liabilities and stockholders' deficiency																																														168,626	65,611	76,847
lion biotechnologies, inc.
condensed statements of operations
revenues
costs and expenses
operating expenses (including 2,139,927,
697,671, 2,360,345, 2,357,370 and 9,749,073
in share based compensation costs)																																														2,459,063
cost of lion transaction																																														6,700,000
research and development																																														250,000	270,000	886,000
impairment of intangible asset
total costs and expenses																																														9,409,063	1,646,425	3,136,133
income from operations																																														-9,409,063	-1,646,425	-3,136,133
other income
interest expense																																															-110,810	-88,472
change in fair value of derivative liabilities																																															1,927,839	-2,548,074
amortization of discount on notes
cost to induce exchange transaction
financing costs
total other income																																															1,319,141	-2,636,546
net income																																														-9,409,063	-327,284	-5,772,679
net income per share																																														-0.66	0	0.07
weighted-average common shares
outstanding, basic and diluted																																														14,152,052	78,293,095	78,136,665
deposits and prepaid expenses																																															8,628	34,050
property and equipment, net of accumulated
depreciation of 5,809 and 2,704																																															25,244
rent deposit																																															16,000	16,000	16,000
accrued expenses - national institute of health																																															616,000	866,000
12% secured promissory notes																																															1,216,250
7% convertible promissory notes																																															5,000,000	5,000,000
derivative liabilities																																															8,740,110	10,667,947	6,292,388
78,293,095 and 77,993,591 shares issued and outstanding, respectively																																															3,262	3,262
common shares to be issued with 12% secured promissory notes																																															497,888
operating expenses (including 469,486,
9,211,000, 1,696,712, 9,251,302 and 13,855,121
in share-based compensation costs)																																															1,376,425
amortization of discount on convertible notes																																															-497,888
private placement costs
depreciation of 4,257 and 2,704																																																26,797
intellectual property licenses, net of accumulated amortization of
217,408 and 217,408
bank overdraft																																																17,619
operating expenses (including 1,227,227
40,302, and 15,835,268 of non-cash
share-based compensation costs)																																																2,250,133
advance to related party																																																	50,000
deposit																																																	17,500	7,500	7,500	5,000	150	150	150
property and equipment, net of accumulated depreciation of 1,513 and 0																																																	18,803
intellectual property licenses, net of accumulated amortization of 111,723 and 57,372																																																	105,685
accrued interest																																																	31,644
unsecured convertible promissory notes, net of discount																																																	2,598,425
advances to related party																																																		50,000	50,000
property and equipment, net of accumulated depreciation of 595 and 0																																																		16,299
intellectual property licenses, net of accumulated amortization of 93,606 and 57,372																																																		123,802
derivative liability																																																		1,739,473	698,621	792,575	546,730
intellectual property licenses, net of accumulated amortization of 75,489 and 57,372																																																			141,919
website, net of accumulated amortization of 3,667 and 2,442
intellectual property licenses, net of accumulated amortization of 57,372																																																				160,036
due to director																																																							18,137
website, net of accumulated depreciation of 347 and 2,442																																																					1,734
intellectual property licenses																																																					217,408	217,408	217,408
common stock; 0.000041666 par value; 1,800,000,000 shares authorized; 72,793,349 and 121,440,000 shares issued and outstanding, respectively																																																					3,033
website, net of accumulated depreciation of 173																																																						1,908
common stock; 0.000041666 par value; 1,800,000,000 shares authorized; 71,860,008 and 121,440,000 shares issued and outstanding, respectively																																																						2,994	2,994
website, net of accumulated depreciation																																																							2,081

We provide you with 20 years of balance sheets for Iovance Biotherapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Iovance Biotherapeutics. Explore the full financial landscape of Iovance Biotherapeutics stock with our expertly curated balance sheets.

The information provided in this report about Iovance Biotherapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.